Figure 3.

One-year persistence was observed in 29 patients (78.4%); these patients remained on inhaled iloprost continuously for 1 year post-transition. Four patients (10.8%) discontinued inhaled iloprost during the first 90 days of the post-transition period (mean time to discontinuation = 37.3 ± 15.7 days). Reasons for discontinuation during the post-transition period included clinical deterioration (n= 7), adverse events (n= 1), and other (non-compliance [n= 1] and joined oral prostacyclin drug study [n= 1]).